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ABSTRACT
Radiotherapy (RT), together with a direct cytolytic effect on tumor tissue, also 
elicits systemic immunological events, which sometimes result in the regression of 
distant metastases (abscopal effect). We have shown the safety and anti-tumor activity 
of a novel metronomic chemotherapy (mCH) regimen with dose-fractioned cisplatin, 
oral etoposide and bevacizumab, a mAb against the vasculo-endothelial-growth-
factor (mPEBev regimen), in metastatic non-small-cell-lung cancer (mNSCLC). This 
regimen, designed on the results of translational studies, showed immune-modulating 
effects that could trigger and empower the immunological effects associated with 
tumor irradiation. In order to assess this, we carried out a retrospective analysis in 
a subset of 69 consecutive patients who received the mPEBev regimen within the 
BEVA2007 trial. Forty-five of these patients, also received palliative RT of one or 
more metastatic sites. Statistical analysis (a Log-rank test) revealed a much longer 
median survival in the group of patients who received RT [mCH vs mCH + RT: 12.1 
+/-2.5 (95%CI 3.35-8.6) vs 22.12 +/-4.3 (95%CI 11.9-26.087) months; P=0.015] 
with no difference in progression-free survival. In particular, their survival correlated 
with the mPEBev regimen ability to induce the percentage of activated dendritic cells 
(DCs) (CD3-CD11b+CD15-CD83+CD80+)  [Fold to baseline value (FBV) ≤1 vs >1: 
4+/-5.389 (95%CI,0- 14.56) vs 56+/-23.05 (95%CI,10.8-101.2) months; P:0.049)] 
and central-memory- T-cells (CD3+CD8+CD45RA-CCR7+) [FBV ≤1 vs >1: 8+/-5.96 
(95%CI,0-19.68) vs 31+/-12.3 (95%CI,6.94-55.1) months; P:0.045].
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INTRODUCTION
Non-small cell lung cancer (NSCLC) is the 
most common malignancy and the leading cause of 
cancer death, representing 17% of new cases of cancer 
diagnosed worldwide [1, 2]. Chemotherapy with platinum 
derivatives in combination with a second cytotoxic drug 
(gemcitabine, pemetrexed or taxans) is recommended 
for patients in advanced stage of disease (stage IIIB-
IV) and no driver mutations/rearrangements, which, 
on the other hand, require molecular targeted specific 
drugs against EGFR or EML-ALK [3-5]. Further on, the 
addiction of Bevacizumab, an anti-angiogenic mAb that 
targets the vasculo-endothelial-growth-factor (VEGF), 
to the chemotherapy is recommended in patients with 
non-squamous histology being able to prolong their 
progression-free (PFS) and overall survival (OS). On 
the overall, PFS and OS of advanced NSCLC patients 
are in a range of 7-8 and 12-13 months, respectively. 
More recently, the clinical development of immune-
check point blockade offers new treatment opportunities 
for these patients. In fact, mAbs to programmed cell 
death receptor-1 (PD-1) and PD-1 ligand-1 (PDL-1) 
may improve their survival by rescuing pre-existing 
tumor-specific cytotoxic-T-cells (CTLs) in the tumor 
sites [6-11]. Tumor specific-CTLs may rise in NSCLC 
patients in response to the processing and cross-priming 
of antigenic material spontaneously released in a context 
of an immunogenic danger signal by the tumor cells 
or as consequence of previous antitumor treatments, 
including CH and/or RT. The latter strategy in particular, 
alone or in combination with CH, represents a powerful 
palliative treatment in advanced NSCLC patients [12-
17]. Most recent technological developments, including 
intensity/volumetric modulated arc therapy (IMRT/
VMAT), image-guided RT (IGRT), 4D-conformal RT 
simulation and proton therapy, have greatly reduced the 
occurrence of adverse events, and its use is achieving 
excellent palliative results in term of symptom relief and 
in term of symptom relief and quality of life in patients 
with  life-threatening metastases, mostly to bone, intra-
thoracic and central nervous system lesions, and more 
rarely to the testicles [18-26]. Although RT is generally 
considered as a loco-regional anticancer means, a number 
of studies have largely demonstrated its ability to elicit 
complex immune-adjuvant effects. RT may, in fact, induce 
immunogenic cell death and peri-tumoral inflammation, 
thus converting the irradiated tumor tissue in a functional 
“in situ” antitumor vaccine with consequent poly-antigen 
specific CTL responses [27-29]. At this purpose, these 
immune-biological effects have been advocated to explain 
the sporadic occurrence of tumor regressions outside the 
irradiation site in cancer patients undergone palliative 
RT with no other concomitant systemic anticancer 
treatments [30-33]. This phenomenon recognized in the 
50ths by Mule et al. was designated as “abscopal effect” 
[30-33]. On these bases, several trials are currently 
testing RT in combination with immunotherapy and/or 
immune-checkpoint blockade in patients with a number 
of different malignancies [28, 30, 34, 35] including 
malignant melanoma [34], prostate adenocarcinoma [35], 
and NSCLC. Several cytotoxic drugs and CH schedules 
have shown immune-modulating effects similar to RT. 
Metronomic chemotherapy (mCH) or dose-dense CH, 
is an alternative anti-cancer strategy based on the use 
of conventional cytotoxic drugs administered at lower 
dosage for a prolonged period of time [36]. This treatment 
modality allows the achievement of a higher dose-
intensity of target cytotoxic drugs compared to traditional 
usage, avoiding dangerous peaks in blood concentration 
and, consequently, showing a more tolerated toxicological 
profile and different antitumor activity. The antitumor 
activity of mCH derives by a combination of different 
mechanisms concerning: a direct cytotoxic effect on tumor 
cells (anti-blastic effect), pro-angiogenic precursors (anti-
angiogenic effect), immunosuppressive regulatory-T-cells 
(Tregs) and myeloid-derivative-suppressor-cells (MDSCs) 
(immune-modulating effects). Additionally, it may 
induce neo-antigen and gene modulation in tumor cells 
(epigenetic effect) and constant release of tumor-derived 
antigens in a context of immunogenic cell death (immune-
stimulating effects) [36, 37]. We previously showed that a 
metronomic regimen with dose-fractioned cisplatin, oral 
etoposide and bevacizumab (mPEBev) is a safe and very 
active treatment for advanced NSCLC patients enrolled 
in the two-step phase I-IIb BEVA2007 trial [38-41]. An 
immune-biological monitoring performed on these patients 
along the treatment, revealed its ability to decrease the 
serum levels of multiple proangiogenic factors (VEGFA, 
Angiopoietin 2 and Follistatin), and cytokines (IFNɣ, 
IL4 and IL17A). This treatment was also associated to a 
progressive increase of different circulating immune-cell 
lineages including activated CTLs (CD3+CD8+CD62L+), 
long-term effector-memory- (CD3+CD8+CD27+) and 
central-memory-T-cells (TCMs; CD3+CD8+C45RA-
CCR7+). The BEVA2007 trial was enforced by a 
functional study on in vitro cultured peripheral blood 
mononuclear cells (PBMCs) derived from the enrolled 
patients. The results of this ancillary study revealed the 
ability of the mPEBev regimen to give rise to an efficient 
DC activity in the cultures and to promote an increased 
antigen-specific T-cell proliferation and Th1 cytotoxic 
These results suggest that tumor irradiation may prolong the survival of NSCLC 
patients undergone mPEBev regimen presumably by eliciting an immune-mediated effect 
and provide the rationale for further perspective clinical studies.
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response in NSCLC patients [39-41]. We have, therefore, 
hypothesized that the immune-modulating properties 
of the mPEBev regimen could empower the systemic 
immunological effect potentially ignited by conventional 
RT. In order to test this hypothesis, we carried out a 
retrospective analysis aimed to investigate whether the 
use of RT, given on palliative setting, could improve the 
outcome of NSCLC patients who received the mPEBev 
mCH regimen.
RESULTS
Study design
We carried out a retrospective analysis on sixty-
nine consecutive patients with metastatic non-squamous 
NSCLC enrolled in the step 2 of the BEVA2007 trial 
between September 2007 and September 2015. Patients 
who completed four treatment cycles according to the 
mPEBev regimen were selected for our retrospective 
study. Among these, twenty-four patients received mCH 
alone and their features are presented in the Table 1. The 
remaining forty-five patients, 37 males and 8 females, with 
median age of 63 years and a median ECOG performance 
status of 1, presented symptomatic lesions and required 
concurrent palliative RT on selected sites (Table 1). 
Nineteen of the latter patients received RT to the bones; 
seven to thoracic lesions (five lung and two nodes); 
twenty-one to brain (eighteen WBRT and three SRS). 
Sixteen patients with bone metastases received 30 Gy in 
ten RT fractions, while three patients received further 20 
Gy in five fractions. The treatment resulted safe in patients 
with advanced NSCLC undergoing to mCH and RT. Thirty 
Gy in ten RT fractions were planned for patients who 
received WBRT; while 54 Gy in 30 RT fractions were 
planned for patients who needed thoracic irradiation. Brain 
SRS was instead administered as 20 Gy in one single 
fraction. No significant adverse events or toxicity-related 
interruptions were recorded for these patients, and all of 
them could complete the pre-planned treatment program. 
However, there was a moderate hematological toxicity 
in both groups, mainly consisting in reversible grade 1-3 
leucopenia (6 cases in the mCH group vs 8 cases in the 
mCH plus RT group) rapidly recovered with the use of 
growth factors, grade 2 anemia (6 cases in the mCH group 
vs 8 cases in the mCH plus RT group). In addition, only a 
light-moderate grade of skin toxicity and a grade 3 post-
attinic esophagitis (1 case) were observed in the group 
of patients undergoing mCH plus RT. Palliative RT was 
administered after two and four mPEBev courses in 10 and 
35 patients, respectively. 
Radiotherapy and survival
Kaplan-Meier curves and log-rank tests did not 
record difference between patients who received mCH 
alone and those who received mCH + RT in term of PFS. 
Conversely, a much longer survival was recorded in the 
second group of patients [mCH vs. mCH+RT: 12.1 +/-
2.5 (95%CI 3.35-8.6) vs. 22.12 +/-4.3 (95%CI 11.9-26.1) 
months; P = 0.015] (Figure 1A, 1B). Kaplan Meyer curves 
and log-rank tests on the group of patients who received 
RT did not disclose significant correlations between 
either PFS or OS and with: a) sex, b) grading, c) ECOG 
performance status score (1 < vs. ≥1) and type response 
(PR vs SD) to the mCH (data not shown). 
Immunomodulation and survival
We then investigated whether the longer survival 
recorded in patients who received RT and mCH could have 
some correlation with the immunological effects induced 
by the mPEBev regimen in NSCLC patients and described 
in a previous report [41]. Our analysis revealed a much 
longer survival in those patients who received RT + mCH 
and presented a mPEBev-related increase in activated DCs 
(CD3-CD11b+CD15-CD83+CD80+) [FBV ≤1 vs > 1: 4+/-
5.389 (95%CI,0-14.56) vs 56+/-23.05 (95%CI,10.8-101.2) 
months; p:0.049)] and peripheral TCMs [FBV ≤1 vs > 1: 
8+/-5.96 (95%CI,0-19.68) vs 31+/-12.3 (95%CI,6.94-
55.1) months; p:0.046] (Figure 1C, 1D and Figure 2). 
We were instead unable to demonstrate the same survival 
correlation in patients who received the mCH alone 
with the treatment-related increase in these blood cell 
populations [DC, FBV ≤1 vs > 1; 14.6+/-5.618 (95%CI 
0-12.046) vs 6+/-1.35 (95%CI1.6-10.325) months, P = 
0.800; TCMs FV ≤1 vs > 1: 17.7+/-1063 (95%CI 3.54-
8.46) vs 10.7+/-3.84 (95%CI,1.4 4.55); P = 0.559], (Figure 
1E, 1F). Our statistical analysis failed to demonstrate any 
other survival correlation with baseline and mCH-related 
changes in the serum levels of proangiogenic factors 
(VEGFA, Angiopoietin 2 and Follistatin), cytokines 
[Interferon (IFN)ɣ, IL4 and IL17A] and Tregs, NKs or 
MDSC (data not shown).
DISCUSSION
Our retrospective analysis, carried out on advanced 
NSCLC patients who completed four mPEBev regimen 
courses and received concomitant or subsequential 
palliative radiotherapy, revealed a 78% disease control rate 
(CR+PR+SD) with an OS over 23 months and a 66% one-
year survival rate. These patients presented a much longer 
OS if compared with a homologous group of patients 
enrolled in the same BEVA2007 trial and who underwent 
the same mCH regimen with no progression along the 
treatment, who did not receive RT. Our analysis showed 
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Figure 1: Representation of PFS and OS of patients. PFS A. and OS B. of patients undergone mCH and mCH + RT. Figure also 
represents OS of patients undergone mCH C., D. and mCH + RT E., F. with fold to baseline value of activated dendritic cells C. and E. 
and central memory T cells D. and F. ≤ 1 or > 1. The percentage of activated dendritic cells and central memory T cells was evaluated on 
the PBMCs isolated from patients at baseline and after four mCH courses, by performing a multicolor immune-cytoflurimetric analysis, as 
described in a previous study on the same patients. 
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that the OS of patients who received mCH + RT did not 
correlate with RT modality, dosage or site of irradiation. 
Interestingly, the two populations of patients who received 
mCH or mCH + RT did not show statistical difference in 
term of PFS, a fact that suggests a systemic therapeutic 
effects in the latter group of patients which results in a 
prolonged survival.
Even though significant bias exists, due to the small 
sample, and the retrospective nature of the study, these 
results appear intriguing. In fact, the most promising 
systemic treatments for inoperable NSCLC patients 
present a median OS barely longer than 12-14 months 
[3-5]. Additionally, no information, concerning the 
putative ability of palliative RT to prolong the survival 
in patients who receive standard chemotherapy +/- 
bevacizumab is currently available. We have hypothesized 
that our metronomic CH regimen may help RT to elicit 
an immune-mediated response, with potential antitumor 
activity as described in the literature [32, 33, 42]. This 
hypothesis is strongly supported by the finding that the 
survival of patients who received mCH + RT is correlated 
with the mPEBev-dependent increase in activated DCs 
and TCMs. In line with these results, preclinical findings 
suggest that RT-induced tumor cell death and peri-tumoral 
inflammation modulate the immune-system’s ability to 
activate antigen presenting cells-mediated cross-priming 
and additional immune-effects (immunogenic cell death). 
Exposure of tumor cells to ionizing radiation can result in 
immunogenic cell death, whereby upregulation or release 
of new tumoral antigens and of Damage-Associated-
Molecular-Patters (DAMPs), Heat-Shock-Proteins and 
High-Mobility-Group-Box-1 (HMGB1), recognized by 
the toll like receptor-4 (TLR-4) on the surface of DCs, 
promotes both maturation and activity of DCs [42, 43]. 
Therefore, the release of DAMPs associated with RT-
induced cancer cell death occurs in a dose-dependent 
fashion and has been shown to recruit and stimulate DCs 
to uptake tumor antigens and cross-present them to naïve 
T cells thus initiating anti tumor immune responses. 
RT can also facilitate the recruitment of effector T-cells 
to the tumor by inducing the secretion of CXC motif 
chemokine ligand CXCL9, CXCL10 and CXCL16 by 
tumor cells [1, 2]. RT is able to induce upregulation of 
major histocompatibility complex class I molecules, FAS/
CD95, and stress-induced natural killer group 2D-ligands 
on tumor cells by enhancing recognition and killing of 
tumor cells by CTls [1, 3, 4]. Thus, all radio-induced 
immunological effects convert the irradiated tumor cells 
into an “in situ vaccine”, resulting in immunogenic cell 
death and activation of a systemic antitumor immune 
response [42-44]. In this context, it has been shown that 
the sequential or concomitant combination of RT with 
anticancer vaccines elicits a very efficient multi-antigen 
T cell antitumor response in mouse models that leads to 
longer survival compared with either vaccine-therapy or 
RT alone [6, 45]. 
On these basis, we can speculate the existence of an 
additive antitumor effect between mPEBev mCH and RT 
potentially related to clear immune-biological effects of 
both treatment modality. The mPEBev-related increase in 
the percentage of activated DCs could in fact, empower the 
cross-priming of antigen released by the irradiated tumor 
tissue, with a consequential amplified anti-tumor T cell 
response. In this contest, TCMs represent an effector-T-
Table 1: Clinical features and treatment of sixty-nine patients (pts) enrolled in the BEVA2007 trial. 
Features Patients who received palliative RT (45 patients)
Patients who did not receive palliative RT (24 
patients)
Sex
Male 37 (82.2%) 16 (66.7%)
Female 8 (17.8%)  8 (33.3%)
RT sites
1Bone 19 (42.2%) NA
2Lung 5 (11.1%) NA
3Nodes 2 (4.4%) NA
4WBRT 18 (40%) NA
5SRS brain 3 (6.7%) NA
Histology
Adenocarcinoma 31 (68.9%) 16 (66.7%)
Squamous 7 (15.6%) 2 (8.3%)
Large cell carcinoma 1 (0.2%) 4 (16.7%)
NAS 6 (13.3%) 2 (8.3%)
Patients received four mCH courses according to the mPEBev regimen, and did not show progression of disease along the 
treatment. Forty-five of these patients received additional palliative radiotherapy (RT) on quality of life threatening lesions.
Radiotherapy Treatment and dosage: 1Thirty Gy in ten RT fractions (three patients received additional treatment with 20 Gy 
in five fractions); 2-3Fifty-four Gy in 30 RT fractions; 4Thirty Gy in ten RT fractions; 5Twenty Gy in one single fraction.
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cell subset with long term memory and high tumor killing 
activity, which are able to achieve distant lymph-nodes and 
tumor sites due to the expression of chemokine receptors 
(CCR)-7 on their surface [46, 47]. However, despite of 
the immune-stimulatory effects of both mPEBev regimen 
and RT, cancer recurrence and/or progression occurs in the 
majority of patients due to immune-escape mechanisms 
in the long term. In this context PD-1/PDL1 immune-
check point blockade with mAbs could be a promising 
therapeutic salvage tool in these patients. In general, the 
main limitation of these immune-checkpoint blocking 
agents is represented by an inefficient tumor specific 
CTL response and by a low CTL-tumor infiltration rate 
which precedes the immune-checkpoint blockade. At this 
purpose a rationale combination of PD-1/PDL1 blockade 
with treatments, like chemotherapy, RT or cancer vaccines, 
able to elicit an efficient CTL response that could produce 
more than additive therapeutic results in these patient has 
already been proposed. In this context, Deng et al. showed 
that RT-mediated inflammation results in IFNγ release thus 
increasing PDL-1 expression on cancer cells, MDSCs, 
and M2-macrophages in tumor microenvironment [30] 
and also reported that the combination of RT and mAbs to 
PDL- 1 enhances the frequency of the abscopal events and 
the antitumor activity of both treatment modalities [30]. 
In conclusion, although with significant limitation, 
our results suggest that RT delivered on a palliative 
setting prolongs the survival of advanced NSCLC patients 
who have received the mPEBev regimen presumably by 
igniting an immunological effect. This effects seems to be 
correlated to the development of antigen presenting cells 
like DCs and consequently to the expansion of activated 
effector T cells with antitumor activity. On these basis, this 
sequential module of treatment which involves mPEBev 
regimen + stereotactic RT deserves to be investigated 
in further prospective trials in NSCLC patients possibly 
in sequential combination with immune-checkpoint 
blockade. 
Figure 2:  Immuno cytofluorimetric analysis performed on the PBMCs of a representative patient. An immuno 
cytofluorimetric analysis performed on the PBMCs of a representative patient and showing baseline and post-treatment expression of 
activated DCs (CD11b+CD83+CD80+) and TCMs (CD3+CD8+CD45A-CCR7+). This analysis shows a significant increase in both cell 
population after four mPEBev courses. A. and C. represent, respectively, pre- and post-treatment expression of TCM; B. and D. represent, 
respectively, pre- and post-treatment expression of CD80.
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PATIENTS AND METHODS
Study design
The study protocol code #BEVA2007 was a two 
step phase I/II clinical trial, performed in accordance to 
the good clinical practice guidelines and was approved 
by the Bioethics Committee of the University of Siena 
as described in previous reports [38-41]. Moreover, 
informed consent was obtained from each subject or 
subject’s guardian. The first step of the study included 25 
patients, who were sub-divided in five cohorts receiving 
escalating dosage of bevacizumab. Cohort 1 received mPE 
chemotherapy alone, while cohort 2, 3, 4 and 5 received 
bevacizumab every three weeks, at the dosage of 2.5, 5, 
7.5 and 10 mg/kg every three weeks [38]. Bevacizumab 
dosage for the second step (Phase II trial) was extrapolated 
by the results of the first step that identified 5 mg/kg as 
the most effective biological dose (MEBD) in combination 
with the mPEBev regimen and 7.5 mg/kg as its maximum 
tolerated dose (MTD). Sixty-nine patients signed a written 
informed consent and were enrolled in the second part 
of the study [39-41]. All the cases were discussed in a 
multidisciplinary tumor board, including a dedicated 
surgeon, medical oncologist, radiation oncologist, 
radiologist, and pathologist. The inclusion criteria were: 
histological diagnosis of mNSCLC, allowing squamous 
cell carcinomas not considered at risk of bleeding, 
performance status (ECOG) from 0 to 2, normal renal 
and hepatic function, WBC count more than 2,500/mm3, 
hemoglobin more than 9 g/dl, platelet cell count more 
than 90,000/mm3, normal cardiac function, and advanced 
stage (IIIB/IV) of disease. The exclusion criteria were: 
Central tumors with high risk of bleeding (excavated with 
bulky necrosis and infiltration of large arterial and venous 
structures) for bevacizumab use, a history of other severe 
cardiovascular disease, arrhythmia, second malignant 
tumors, signs of active infections. 
Treatment schedule
Sixty-nine patients, therefore, received iv. cisplatin 
(30 mg/sqm) on days 1-3 and daily oral etoposide (50 
mg) on from day 1 to day 15 and bevacizumab (5 mg/
kg) on the day 3 every three weeks, for a maximum of 4 
consecutive courses [38-40]. Palliative radiotherapy was 
allowed with palliative intent on quality of-life threatening 
lesions. 
Radiation therapy treatment
RT was delivered on a case by case basis, as a 
palliative treatment. Forty-five of these patients received 
radiation therapy, either as RT to the bones (19 patients), 
WBRT (18 patients) and SRS (3 patients), palliative 
thoracic irradiation (7 patients). RT was delivered 
with a Linear Accelerator (6MV-15MV photon) as a 
3D-conformational radiation therapy (3D-CRT) on 
that. The target volume was identified by diagnostic CT 
scan. RT dosage was prescribed on a case by case basis, 
according to the Clinician choice. CT simulation was 
performed with a 5 mm slicing, 120KV, 10 Index Noise, 
Range 100-440 mA, spiral 16 slices CT Scanner. 
Biological analysis and blood sampling
Peripheral blood samples (10 ml) were withdrawn 
at baseline and one hour before any treatment cycle of 
chemotherapy for either serum and PBMC isolation. 
Serum derived from standard peripheral blood 
centrifugation and PBMCs obtained by Ficoll-Hypaque 
(Celbio S.P.A., Italy) gradient separation medium form 
heparinized blood samples were immediately frozen 
and stored as described in previous studies [38-40]. 
Lymphocytes, platelets, neutrophils, monocytes were 
evaluated by hemocytometric cell counts, while their 
feature was evaluated by microscope analysis. Flow 
cytometry was perfomed on patients’ PBMCs by carrying 
out standard multicolor immuno-cytofluorimetric analysis 
[41] with conjugated anti-CD3, CD4, CD8, CD27, 
CD62L, CD19, CD16, CD56, CD25, CD80, CD83, 
FoxP3, CCR7, CD45Ra, CD11b, CD11c, CD14, CD15 
mAbs all purchased by eBioscience, USA. 
BioPlex assay
Blood samples were collected from a peripheral 
vein at baseline and just before each treatment and 
kept on ice. Serum was collected by centrifugation 
(3,000 rpm for 10 min at 4°C), aliquoted, and stored at 
−80°C until analyzed. A multiplex biometric ELISA-
based immunoassay, containing dyed microspheres 
conjugated with a monoclonal antibody specific for a 
target protein was used according to the manufacturer’s 
instructions (Bioplex, Bio-Rad Lab., Inc., Hercules, CA, 
USA). Soluble molecules were measured using either 
commercially available kits or customized kits for the 
evaluation of the following cytokines: Interleukin(IL)4, 
IL8, IL10, IL12/A, IL17/A, IFNɣ, Tumor necrosis factor 
(TNF)α, VEGF, Granulocyte-Colony Stimulating Factor 
(GCSF), angiopoietin-2 as described in previous papers 
[38-41]. Serum levels of all proteins were determined 
using a Bio-Plex array reader (Luminex, Austin, TX) that 
quantifies multiplex immunoassays in a 96-well plate with 
very small fluid volumes. The analyte concentration was 
calculated using a standard curve, with software provided 
by the manufacturer (Bio-Plex Manager Software).
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Statistical analysis
The between-mean differences were statistically 
analyzed using Stat View statistical software (Abacus 
Concepts, Berkeley, CA). The results were expressed as 
the mean +/- standard deviation (SD) of 4 determinations 
made in three different experiments, and the differences 
determined using the 2-tail Student’s t-test for paired 
samples. In order to perform a survival analysis we 
divided the patients into two subgroups with low (A) and 
high (B) score, according to their respective median value 
of each specific marker or treatment related level change 
expressed as fold change to baseline value. Descriptive 
statistic by Kaplan Meier’s method and Log-Rank test 
were used to evaluate PFS, and OS and correlate them with 
patients’ associated variables. All analyses were performed 
by SPSS statistical package, version 17.0. A p-value of 
0.05 or less was considered statistically significant. In the 
comparative analysis, patients who showed a rapid disease 
progression or severe adverse events or death during the 
induction treatment with the mPEBev regimen and did not 
complete at least three treatment courses were excluded 
from the retrospective study.
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radiosurgery; Gy: gray; PR: partial response; SD: stable 
disease; FBV: fold to baseline value; VEGFA: vascular 
endothelial growth factor A; IFNɣ: Interferon ɣ; DAMPs: 
Damage-Associated-Molecular-Patters;HMGB1: high-
mobility-group-box-1; TLR-4: toll like receptor-4; CCR-
7: chemokine receptors; MEBD: most effective biological 
dose; MTD: maximum tolerated dose; WBC: white blood 
cell; 3D-CRT: 3D-conformational radiation therapy; 
TNFα: tumor necrosis factor α; GCSF: granulocyte-colony 
stimulating factor.
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